Funding Resources
Funding Overview
Funding Strategy

Funding Opportunities

Grant Mechanisms
Training & Career
   Development
Contracts Management
Review Committees
Funding News
Program Areas

Research
Anticonvulsant Screening
   Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
   (TBI) Research
Technology Transfer
   Office

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

Application processes at NIH are changing. Applicant organizations are encouraged to start preparing for this transition by registering with Grants.gov and NIH eRA Commons now.

---

PAS-06-202, CNS Therapy Development for Lysosomal Storage Disorders (R21)
Release Date: March 7, 2006
Announcement Number: PAS-06-202
Application Receipt Date:
June 1, 2006
October 1, 2006
February 16, 2006
June 16, 2006
October 16, 2006   

Funding Contact: Danilo Tagle, Ph.D.
Program Area: Neurogenetics

Brief Description:
The goal of this Funding Opportunity Announcement (FOA) is to solicit applications on lysosomal storage disorders (LSDs) focused on improving CNS treatment outcomes, enhancing the effectiveness of delivery and targeting of cells, enzymes, drugs and genes into the brain, and developing novel therapeutic modalities, such as implantable biocapsules and micro-electro-mechanical systems (MEMS)-based devices. Lysosomal storage disorders constitute a group of recessive genetic diseases resulting from cellular enzymatic deficiencies of acid hydrolases that normally catalyze the metabolism of glycoproteins, glycolipids and other macromolecules, or from defects in transporter proteins leading to pathogenic accumulation of these substances in lysosomes. Treatment modalities for LSDs are currently limited to bone marrow transplantation (BMT) and enzyme replacement therapy (ERT). These approaches while providing significant promise for treatment of the visceral manifestations of LSDs, do little to address CNS pathologies for this group of disorders. Thus this announcement specifically encourages the transition from basic studies in LSDs to translational research for improved delivery of therapeutic cells, proteins, genes, and small molecules across the blood-brain barrier.

Choose an option to view additional funding announcements

New Announcements | Research Area | RFAs Only | PAs Only | RFPs Only | Notices Only | Supplements Only | All Announcements | Archives